RenovoRx Reports 136% Revenue Growth in Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: Yahoo Finance
- Record Quarterly Revenue: RenovoRx achieved a record revenue of $563,000 in Q1 2026, representing a 136% increase compared to Q4 2025, indicating strong growth potential in the cancer treatment market.
- Expansion of Commercial Centers: The number of active commercial cancer centers increased from 8 at the end of 2025 to 16 by May 2026, demonstrating accelerated commercialization and a more diversified future revenue stream.
- Increased Investor Confidence: The company successfully closed an oversubscribed private placement, generating approximately $10 million in funding, reflecting strong market confidence and support for its future development.
- High R&D Expenses: Despite revenue growth, Q1 R&D expenses reached $1.2 million, indicating ongoing investment in technology development while also facing challenges in cost management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.882
Low
3.00
Averages
5.63
High
12.50
Current: 0.882
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RenovoRx (RNXT) Q1 2026 Earnings Transcript
See More
RenovoRx CEO to Participate in Healthcare Showcase
- Commercial Progress Highlight: RenovoRx achieved record sales of $563,000 in Q1 2026 from RenovoCath as a standalone drug-delivery device, indicating strong demand and growth potential in the oncology market.
- Clinical Trial Advancement: The ongoing Phase III TIGeR-PaC trial is expected to complete enrollment by June 2026, providing critical data for evaluating the efficacy of the novel drug-device combination in locally advanced pancreatic cancer, which may drive future market applications.
- Research Support Initiatives: RenovoRx is actively supporting investigator-initiated trials for borderline resectable and metastatic pancreatic cancer, which not only provide valuable data for the TAMP therapy platform but also potentially broaden its clinical application and enhance market competitiveness.
- Showcase Participation: CEO Shaun Bagai and CFO Mark Voll will participate in the AGP Annual Healthcare Company Showcase on May 20, 2026, discussing the company's commercial progress and clinical research, which is expected to attract investor interest and enhance the company's visibility.
See More
RenovoRx Reports 136% Revenue Growth in Q1 2026
- Record Quarterly Revenue: RenovoRx achieved a record revenue of $563,000 in Q1 2026, representing a 136% increase compared to Q4 2025, indicating strong growth potential in the cancer treatment market.
- Expansion of Commercial Centers: The number of active commercial cancer centers increased from 8 at the end of 2025 to 16 by May 2026, demonstrating accelerated commercialization and a more diversified future revenue stream.
- Increased Investor Confidence: The company successfully closed an oversubscribed private placement, generating approximately $10 million in funding, reflecting strong market confidence and support for its future development.
- High R&D Expenses: Despite revenue growth, Q1 R&D expenses reached $1.2 million, indicating ongoing investment in technology development while also facing challenges in cost management.
See More
RenovoRx Q1 Earnings Report Analysis
- Earnings Performance: RenovoRx reported a Q1 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability, while revenue reached $0.56 million, up 180% year-over-year, exceeding expectations by $0.1 million, suggesting improved market demand.
- Cash Flow Status: As of March 31, 2026, the company had approximately $12.4 million in cash and cash equivalents, indicating relatively healthy liquidity, and raised about $10 million in gross proceeds from a private placement in Q1, further strengthening its financial stability.
- Operational Funding Assurance: The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027, indicating a robust cash flow position that supports ongoing business development in the near term.
- Annual Revenue Guidance: RenovoRx reiterated its full-year 2026 revenue guidance of $3 to $4 million, reflecting confidence in future revenue growth despite profitability pressures, as the company actively seeks market opportunities.
See More
RenovoRx Named 10th Most Innovative Medical Device Company by Fast Company
- Innovative Company Ranking: RenovoRx has been recognized by Fast Company as the 10th most innovative medical device company in 2026, highlighting its innovation capabilities in cancer treatment and enhancing its brand image in the industry.
- Commercialization Progress: In 2025, RenovoCath generated approximately $1.1 million in sales, indicating a growing market penetration in cancer centers and increasing physician recognition of its targeted drug delivery technology.
- Market Potential Assessment: RenovoRx estimates that the initial total addressable market for RenovoCath is around $400 million, with the potential to reach multi-billion dollar sales opportunities as the platform expands into additional solid tumor indications, further solidifying its market position.
- Technology Platform Advantage: The Trans-Arterial Micro-Perfusion (TAMP™) therapy enabled by RenovoCath allows for targeted drug delivery, potentially reducing treatment toxicities and improving efficacy, aligning with the company's mission to enhance the quality of life for cancer patients.
See More
RenovoRx Reports Wider Net Loss Despite Revenue Growth in 2025
- Financial Performance: RenovoRx's net loss for 2025 widened to $11.2 million from $8.8 million last year, despite revenue growth from $43,000 to $1.12 million, indicating initial market acceptance of its products.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.02 million in cash and cash equivalents, with recent private placement proceeds providing around $13 million to support upcoming key milestones.
- Clinical Trial Progress: The company is advancing its Phase III TIGeR-PaC clinical trial evaluating intra-arterial delivery of gemcitabine via the RenovoCath device, with plans to complete enrollment of 114 patients by mid-2026.
- Market Potential: The initial total addressable market for RenovoCath as a stand-alone device is estimated at $400 million, with the CEO asserting that the company has the necessary funding and infrastructure to drive execution towards critical milestones.
See More
RenovoRx (RNXT) Q1 2026 Earnings Transcript
See More
RenovoRx CEO to Participate in Healthcare Showcase
- Commercial Progress Highlight: RenovoRx achieved record sales of $563,000 in Q1 2026 from RenovoCath as a standalone drug-delivery device, indicating strong demand and growth potential in the oncology market.
- Clinical Trial Advancement: The ongoing Phase III TIGeR-PaC trial is expected to complete enrollment by June 2026, providing critical data for evaluating the efficacy of the novel drug-device combination in locally advanced pancreatic cancer, which may drive future market applications.
- Research Support Initiatives: RenovoRx is actively supporting investigator-initiated trials for borderline resectable and metastatic pancreatic cancer, which not only provide valuable data for the TAMP therapy platform but also potentially broaden its clinical application and enhance market competitiveness.
- Showcase Participation: CEO Shaun Bagai and CFO Mark Voll will participate in the AGP Annual Healthcare Company Showcase on May 20, 2026, discussing the company's commercial progress and clinical research, which is expected to attract investor interest and enhance the company's visibility.
See More
RenovoRx Reports 136% Revenue Growth in Q1 2026
- Record Quarterly Revenue: RenovoRx achieved a record revenue of $563,000 in Q1 2026, representing a 136% increase compared to Q4 2025, indicating strong growth potential in the cancer treatment market.
- Expansion of Commercial Centers: The number of active commercial cancer centers increased from 8 at the end of 2025 to 16 by May 2026, demonstrating accelerated commercialization and a more diversified future revenue stream.
- Increased Investor Confidence: The company successfully closed an oversubscribed private placement, generating approximately $10 million in funding, reflecting strong market confidence and support for its future development.
- High R&D Expenses: Despite revenue growth, Q1 R&D expenses reached $1.2 million, indicating ongoing investment in technology development while also facing challenges in cost management.
See More
RenovoRx Q1 Earnings Report Analysis
- Earnings Performance: RenovoRx reported a Q1 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability, while revenue reached $0.56 million, up 180% year-over-year, exceeding expectations by $0.1 million, suggesting improved market demand.
- Cash Flow Status: As of March 31, 2026, the company had approximately $12.4 million in cash and cash equivalents, indicating relatively healthy liquidity, and raised about $10 million in gross proceeds from a private placement in Q1, further strengthening its financial stability.
- Operational Funding Assurance: The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027, indicating a robust cash flow position that supports ongoing business development in the near term.
- Annual Revenue Guidance: RenovoRx reiterated its full-year 2026 revenue guidance of $3 to $4 million, reflecting confidence in future revenue growth despite profitability pressures, as the company actively seeks market opportunities.
See More
RenovoRx Named 10th Most Innovative Medical Device Company by Fast Company
- Innovative Company Ranking: RenovoRx has been recognized by Fast Company as the 10th most innovative medical device company in 2026, highlighting its innovation capabilities in cancer treatment and enhancing its brand image in the industry.
- Commercialization Progress: In 2025, RenovoCath generated approximately $1.1 million in sales, indicating a growing market penetration in cancer centers and increasing physician recognition of its targeted drug delivery technology.
- Market Potential Assessment: RenovoRx estimates that the initial total addressable market for RenovoCath is around $400 million, with the potential to reach multi-billion dollar sales opportunities as the platform expands into additional solid tumor indications, further solidifying its market position.
- Technology Platform Advantage: The Trans-Arterial Micro-Perfusion (TAMP™) therapy enabled by RenovoCath allows for targeted drug delivery, potentially reducing treatment toxicities and improving efficacy, aligning with the company's mission to enhance the quality of life for cancer patients.
See More
RenovoRx Reports Wider Net Loss Despite Revenue Growth in 2025
- Financial Performance: RenovoRx's net loss for 2025 widened to $11.2 million from $8.8 million last year, despite revenue growth from $43,000 to $1.12 million, indicating initial market acceptance of its products.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.02 million in cash and cash equivalents, with recent private placement proceeds providing around $13 million to support upcoming key milestones.
- Clinical Trial Progress: The company is advancing its Phase III TIGeR-PaC clinical trial evaluating intra-arterial delivery of gemcitabine via the RenovoCath device, with plans to complete enrollment of 114 patients by mid-2026.
- Market Potential: The initial total addressable market for RenovoCath as a stand-alone device is estimated at $400 million, with the CEO asserting that the company has the necessary funding and infrastructure to drive execution towards critical milestones.
See More
